Skip to content

Eladi kasaya in the management of Asrigdara

Evaluation of comparative efficacy of Eladi kasaya versus Tab Tranexamic acid in the management of Asrigdara (Heavy menstrual bleeding).

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/048303
Enrollment
92
Registered
2022-12-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N920- Excessive and frequent menstruation with regular cycle

Interventions

None listed

Sponsors

Mahatma gandhi ayurved college, hospital and research centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who are willing to give written consent for the trial. 2. Patients between the age group of 18 to 45years. 3. Patients with excessive bleeding ( >80ml) for at least 2 consecutive cycles.

Exclusion criteria

Exclusion criteria: 1. Patients with any diagnosed uterine organic pathology like Uterine Fibroid, Adenomyosis, Chronic tubo ovarian mass. Polycystic ovaries 2. Patients with systemic diseases like hypertension, diabetes mellitus, congestive cardiac failure etc. 3. Patients with coagulopathy 4. Liver dysfunction 5. Thyroid dysfunction 6. Patients with malignancy or undiagnosed neoplasm. 7. Patients with history of recent abortion. 8. Patients with active genital tuberculosis. 9. Bleeding from the polyps and erosion. 10. IUCD in utero, pelvic endometriosis. 11. Hb

Design outcomes

Primary

MeasureTime frame
reduction of blood loss calculated by pictorial blood assessment chart Timepoint: 0,4weeks, 8weeks, 12weeks, 16weeks

Secondary

MeasureTime frame
improvement in hemoglobinTimepoint: 0 and 16 weeks;quality of life assessment using menorrhagia impact quessionnaireTimepoint: 0 and 16 weeks;reduction in pain assessed by visual analog scaleTimepoint: 4weeks, 8weeks, 12 weeks, 16weeks;safety of given medication through occurance of adverse drug reaction Timepoint: 4,8,12 week

Countries

India

Contacts

Public ContactDr Pratiksha P Rathod

Mahatma gandhi ayurved college, hospital and research centre

pudgal9@gmail.com9975578364

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026